Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
(Bloomberg)

Medtronic gets U.S. subpoena on brain stimulators

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

Medtronic Inc., the largest maker of heart devices, said it received a subpoena from the U.S. Attorney in western New York related to sales, marketing and reimbursement practices for its brain stimulation products.

Medtronic received the U.S. inquiry on Oct. 14 and is cooperating with the investigation, the Minneapolis-based company said today in a regulatory filing.

Medtronic has received numerous inquires from authorities about its business practices, but this is the first the company has identified related to its neurostimulation devices.

The Medtronic neuromodulation division reported sales of $1.6 billion last year. The unit makes stopwatch-size implantable devices that are used to reduce chronic pain, stimulate movement for such diseases as Parkinson's and treat psychiatric disorders.

"We have no comment beyond what we state in the filing," Medtronic spokesman Brian Henry said today in an e-mail.

Copyright 2010 Bloomberg.